Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Euglycaemic diabetic ketoacidosis

Endocrinology and metabolism · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Suspected euglycaemic DKA needs immediate ketone and venous pH testing and the adult DKA response; do not wait for marked hyperglycaemia. Stop any SGLT2 inhibitor, use ABCDE, obtain monitored access and involve acute and diabetes specialists. Pregnancy, shock, reduced consciousness, severe acid–base disturbance or diagnostic uncertainty requires urgent senior and critical-care or obstetric escalation.

Synopsis

Detect ketoacidosis despite modest glucose, identify SGLT2 and physiological drivers, and maintain insulin with glucose substrate until ketonaemia resolves.

  • Euglycaemic DKA is ketoacidosis with glucose lower than expected for classic DKA, not benign nutritional ketosis with normal acid–base status.
  • SGLT2 inhibitors increase urinary glucose loss, so serious ketogenesis can develop while capillary glucose appears only mildly raised or even within range.
  • Test blood ketones and venous pH in an unwell exposed patient with nausea, vomiting, abdominal pain, dyspnoea, dehydration, drowsiness or unexplained high-anion-gap acidosis.
  • Recognised triggers include acute illness, surgery, reduced carbohydrate or prolonged fasting, dehydration, alcohol excess, insulin omission or reduction and low endogenous insulin reserve.
  • Treat confirmed disease with the dedicated adult DKA fixed-rate insulin pathway; glucose-containing fluid is commonly needed from the outset or early to permit continued insulin safely.
  • Use blood rather than urine ketones for acute monitoring because urine may lag and SGLT2-associated guidance specifically prioritises blood measurement.
  • MHRA advises interruption of SGLT2 treatment for major surgery or acute serious medical illness and restarting only when ketones are normal and the person is stable.
  • After an SGLT2-associated DKA episode, do not restart the drug unless another cause has been identified and resolved and the specialist risk–benefit decision is explicit.

Key red flags

SGLT2 exposure

Current or recently interrupted dapagliflozin, empagliflozin, canagliflozin or ertugliflozin exposure should lower the threshold for blood ketone testing during acute symptoms.

Disproportionate illness

Vomiting, abdominal discomfort, tachypnoea, malaise or drowsiness that seems too severe for the measured glucose may be the key clue to hidden ketoacidosis.

Perioperative setting

Fasting, surgical stress, reduced insulin and dehydration can combine after an operation; medication reconciliation must establish the last SGLT2 dose and current ketones.

Pregnancy-associated risk

Pregnancy accelerates starvation ketosis and changes normal acid–base physiology, so unwell pregnant patients need immediate obstetric and diabetes specialist assessment under the dedicated pathway.

Competing acidosis

Lactate, renal failure, toxic alcohols, salicylate and sepsis may cause or coexist with high-anion-gap acidosis; ketones do not end the diagnostic assessment.

Investigation priorities

01
Blood beta-hydroxybutyrateFirst step

Detect substantial ketonaemia promptly and follow response during insulin therapy.

Management branches

SuspectLook beyond the glucose

An acutely unwell person has SGLT2 exposure, fasting, surgery, pregnancy or insulin deficiency but no marked hyperglycaemia.

  1. Check capillary blood ketones and a venous gas immediately alongside bedside glucose, renal profile, lactate, observations, fluid state and a focused cause assessment.
  2. Stop any SGLT2 inhibitor and confirm the insulin regimen, last doses, food intake and operation or illness timeline without allowing medicines reconciliation to delay resuscitation.
  3. If ketonaemia and acidosis meet the clinical DKA syndrome, activate the adult fixed-rate pathway and senior diabetes input despite a glucose value that appears reassuring.

Key medicines

Fixed-rate intravenous insulin in euglycaemic DKAFollow the adult DKA prescription at 0.1 units/kg/hour while providing sufficient intravenous glucose to maintain safe glycaemia; specialist protocols supersede this in pregnancy, children and unusual insulin sensitivity.Do not reduce or stop the infusion solely for a normal glucose value; instead adjust prescribed substrate and assess ketone clearance. Check potassium, pump delivery and hypoglycaemia risk hourly, with senior review for missed targets or fluid restrictions.
SGLT2 inhibitor after ketoacidosisStop the medicine when DKA is suspected; do not restart after an associated episode unless a different cause has been identified and resolved and an informed specialist decision supports re-exposure.The drug effect may outlast the final tablet. Record the adverse event, check current licensed indication and renal status, provide interruption advice for surgery or serious illness, and do not switch within the class as an automatic workaround.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • MHRA SGLT2 inhibitor ketoacidosis adviceRegulatory recognition, risk-factor, interruption and post-event restarting recommendations.
  • MHRA perioperative SGLT2 interruption updateBlood-ketone monitoring and restart conditions during major surgery or acute serious illness.
  • JBDS 02 management of adult DKAFixed-rate insulin, glucose substrate, potassium, biochemical response and resolution standards.
  • NHS diabetic ketoacidosis overviewNational symptom recognition, ketone safety-netting and urgent-care information.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom